Højer Wang, Linnea;
Wehland, Markus;
Wise, Petra M.;
Infanger, Manfred;
Grimm, Daniela;
Kreissl, Michael C.
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
Beteiligte:
Højer Wang, Linnea;
Wehland, Markus;
Wise, Petra M.;
Infanger, Manfred;
Grimm, Daniela;
Kreissl, Michael C.
Erschienen:
MDPI AG, 2023
Erschienen in:International Journal of Molecular Sciences
Sprache:
Englisch
DOI:
10.3390/ijms24032312
ISSN:
1422-0067
Entstehung:
Anmerkungen:
Beschreibung:
<jats:p>This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic medullary thyroid cancer (MTC). Data on efficacy and safety are presented with the main focus on treatment-related hypertension, a well-known adverse effect (AE) of these TKIs. Taken together, TKI-induced hypertension is rarely a dose-limiting side effect. However, with increasing survival times of patients under treatment, hypertension-associated complications can be expected to be on the rise without proper medication.</jats:p>